This study describes the use of genetically engineered lymphocytes to achieve cancer regression in patients with metastatic melanoma. The researchers used retroviruses to encode T cell receptors (TCRs) in autologous peripheral blood lymphocytes (PBLs), enabling them to recognize and destroy tumor cells. These engineered cells were then transferred into patients who had undergone lymphodepletion. The study found that in 15 patients, the engineered cells engrafted and persisted for at least two months, with some patients showing sustained levels of engineered cells for up to a year. Two patients demonstrated objective regression of metastatic melanoma lesions, indicating the therapeutic potential of genetically engineered cells for cancer treatment. The study highlights the ability of genetically modified PBLs to recognize and destroy tumor cells in vivo. The TCRs were designed to target specific tumor-associated antigens (TAAs) such as MART-1, gp100, NY-ESO-1, and p53. The engineered cells were tested in patients with HLA-A*0201, who had progressive metastatic melanoma. The results showed that the engineered cells persisted in the patients' circulation and were capable of recognizing and destroying tumor cells. The study also found that the persistence of the engineered cells varied depending on the culture conditions and the duration of the ex vivo expansion. The study also discusses the challenges in the persistence and function of the engineered cells, including the potential for mispairing of TCR chains and the decrease in transgene expression over time. However, the functional activity of the engineered cells was sufficient to mediate tumor regression in some patients. The study suggests that further research is needed to improve the expression and function of the transgene, including the use of lentiviral vectors, more powerful promoters, and higher-affinity TCRs. The study also highlights the potential of using genetically engineered PBLs for the treatment of common epithelial cancers.This study describes the use of genetically engineered lymphocytes to achieve cancer regression in patients with metastatic melanoma. The researchers used retroviruses to encode T cell receptors (TCRs) in autologous peripheral blood lymphocytes (PBLs), enabling them to recognize and destroy tumor cells. These engineered cells were then transferred into patients who had undergone lymphodepletion. The study found that in 15 patients, the engineered cells engrafted and persisted for at least two months, with some patients showing sustained levels of engineered cells for up to a year. Two patients demonstrated objective regression of metastatic melanoma lesions, indicating the therapeutic potential of genetically engineered cells for cancer treatment. The study highlights the ability of genetically modified PBLs to recognize and destroy tumor cells in vivo. The TCRs were designed to target specific tumor-associated antigens (TAAs) such as MART-1, gp100, NY-ESO-1, and p53. The engineered cells were tested in patients with HLA-A*0201, who had progressive metastatic melanoma. The results showed that the engineered cells persisted in the patients' circulation and were capable of recognizing and destroying tumor cells. The study also found that the persistence of the engineered cells varied depending on the culture conditions and the duration of the ex vivo expansion. The study also discusses the challenges in the persistence and function of the engineered cells, including the potential for mispairing of TCR chains and the decrease in transgene expression over time. However, the functional activity of the engineered cells was sufficient to mediate tumor regression in some patients. The study suggests that further research is needed to improve the expression and function of the transgene, including the use of lentiviral vectors, more powerful promoters, and higher-affinity TCRs. The study also highlights the potential of using genetically engineered PBLs for the treatment of common epithelial cancers.